Home
Dicerna

Dicerna Market Share Analysis for November 2025

Hear from Novo Nordisk employee Sebastian Parlee, a member of the LGBTQ2+ community, about how he went from seeking community to helping build it.

Health > Biotechnology and Pharmaceuticals

Domaindicerna.com

Year Founded2006

Employees201 - 500

Annual Revenue$100M - $200M

Dicerna

Dicerna (including company regionals)

dicerna.com

See more website traffic and engagement information

Dicerna Revenue up to November 2025 is 100M - 200M

revenue generated by Dicerna top domains

Dicerna top domains revenue over 3 years

Revenue for Dicerna top domains

dicerna.com100M - 200M

See more with Sales Intelligence

Total visits to Dicerna's top domains

Understand Dicerna market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Dicerna's top domains

Analyze Dicerna engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Dicerna's top domains

See how Dicerna keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Dicerna top competitors by domain

Top similar sites in November 2025, ranked by their affinity

avanir.comCompany NameAvanir PharmaceuticalsEmployees501 - 1000HQUnited States, California, Aliso ViejoAnnual revenue$100M - $200MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Dicerna

These are the website technologies, by industry, used by Dicerna top domains

Payment & Currencies (10)

Cart Functionality

Widget (6)

Twemoji

eCommerce (4)

OpenCart

Advertising (3)

DoubleClick

More Technologies

12

See all

News & Signals from Dicerna

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNovonordiskfonden partnered with Dicerna Pharmaceuticals, Inc. on Jan 1st '19.Bagsværd, Denmark-based Novo Nordisk has been working with Dicerna, of Lexington, Mass., since 2019 on therapies that selectively silence genes that cause or contribute to disease.

NewsNovo Nordisk acquired Dicerna Pharmaceuticals, Inc. for $3.3B on Nov 25th '21.Danish drugmaker Novo Nordisk has agreed a $3.3 billion cash deal to buy Dicerna Pharmaceuticals which specializes in therapeutics that counteract disease-causing genes, it said on Thursday.

NewsDicerna Pharmaceuticals, Inc. is developing RNAi therapies via GalXC on Jan 1st '19.Novo Nordisk and Dicerna entered into a research collaboration in 2019 to develop RNAi therapies via GalXC.